NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ALMS

Alumis Inc

Apr 21 • 02:17PM ET

4.73

Dollar change -0.27
Percentage change -5.48	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IBB VTWO IWO IWN SCHA IWC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.45	Insider Own	53.68%	Shs Outstand	47.22M	Perf Week	-27.07%
Market Cap	257.13M	Forward P/E	-	EPS next Y	-3.41	Insider Trans	0.12%	Shs Float	25.20M	Perf Month	32.38%
Income	-294.23M	PEG	-	EPS next Q	-1.54	Inst Own	34.74%	Short Float	16.24%	Perf Quarter	-38.30%
Sales	0.00M	P/S	-	EPS this Y	60.02%	Inst Trans	63.14%	Short Ratio	6.01	Perf Half Y	-57.77%
Book/sh	4.78	P/B	0.99	EPS next Y	17.73%	ROA	-136.66%	Short Interest	4.09M	Perf Year	-
Cash/sh	5.30	P/C	0.89	EPS next 5Y	28.94%	ROE	-198.66%	52W Range	3.18 - 13.53	Perf YTD	-39.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-101.72%	52W High	-65.07%	Beta	-
Dividend TTM	-	Quick Ratio	6.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	48.61%	ATR (14)	1.19
Dividend Ex-Date	-	Current Ratio	6.01	EPS Y/Y TTM	-82.41%	Oper. Margin	-	RSI (14)	41.88	Volatility	16.80% 26.95%
Employees	168	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	21.75
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-129.78%	Payout	-	Rel Volume	0.19	Prev Close	5.00
Sales Surprise	-	EPS Surprise	-24.94%	Sales Q/Q	-	Earnings	Mar 19 AMC	Avg Volume	680.67K	Price	4.73
SMA20	-26.71%	SMA50	-13.25%	SMA200	-48.69%	Trades		Volume	95,880	Change	-5.48%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Today 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -5.48%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Loading…
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
09:00PM	Loading…
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
11:57PM	Loading…
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colowick Alan	Director	Apr 01 '25	Buy	6.97	16,104	112,309	16,104	Apr 03 06:05 PM
Colowick Alan	Director	Apr 02 '25	Buy	7.49	2,300	17,235	18,404	Apr 03 06:05 PM
Babler Martin	President, CEO and Chairman	Apr 01 '25	Buy	6.44	15,650	100,733	106,454	Apr 03 06:05 PM
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc

Upgrade your FINVIZ experience